Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
Filed with ASX · · 3 pages · English
In the deck
Story so far
Earlier from Mesoblast
- Appendix 3B with prospectus
- Mesoblast Receives RMAT For LVAD Heart Failure Patients
- Mesoblasts P3 GVHD Trial Completes Enrollment
- Mesoblast Grants TiGenix License For Treatment of Fistulae
- MSB Named Global Technology Leader In Cell Therapy Industry
Later from Mesoblast
- GVHD Day 28 Results Presentation
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
- Key Day 100 Survival Results In P3 GvHD Trial
- MSB Enters Into US$50M Financing With NovaQuest Capital
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast